The role of diet in triggering human inflammatory disorders in the modern age

Microbes and Infection

Volumn 15, Issue 12, 2013, Pages 765-774

  Huang, Edmond Y ^a   Devkota, Suzanne ^b   Moscoso, Dagmara ^a   Chang, Eugene B ^a   Leone, Vanessa A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

Gut microbiota; High fat; Immunity; Inflammatory disease; Systemic inflammation; Western diet

Indexed keywords

ANTIBIOTIC AGENT; ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; INULIN; MONOUNSATURATED FATTY ACID; OMEGA 6 FATTY ACID; POLYUNSATURATED FATTY ACID; PROBIOTIC AGENT; SATURATED FATTY ACID; TOLL LIKE RECEPTOR;

BIFIDOBACTERIUM; CARBOHYDRATE DIET; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CROHN DISEASE; DIET; ENTERITIS; FECAL MICROBIOTA TRANSPLANTATION THERAPY; FECES MICROFLORA; GENETIC ASSOCIATION; GNOTOBIOTICS; HUMAN; INFLAMMATION; INTESTINE FLORA; LACTOBACILLUS; LACTOBACILLUS REUTERI; LACTOBACILLUS RHAMNOSUS; LIPID DIET; METABOLIC DISORDER; METABOLISM; MICROBIOME; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; PROCEDURES; PROPHYLAXIS; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SHORT SURVEY; ULCERATIVE COLITIS; WESTERN HEMISPHERE;

GUT MICROBIOTA; HIGH-FAT; IMMUNITY; INFLAMMATORY DISEASE; SYSTEMIC INFLAMMATION; WESTERN DIET;

ARTHRITIS, RHEUMATOID; DIET; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY; INFLAMMATORY BOWEL DISEASES; METABOLIC SYNDROME X;

EID: 84884699586     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2013.07.004     Document Type: Short Survey

References (78)

1. Kelly T., Yang W., Chen C.S., Reynolds K., He J. Global burden of obesity in 2005 and projections to 2030. Int. J. Obes. 2008, 32:1431-1437.
2. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005, 55:74-108.
3. Loftus E.V. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004, 126:1504-1517.
4. Molodecky N.A., Soon I.S., Rabi D.M., Ghali W.A., Ferris M., Chernoff G., Benchimol E.I., Panaccione R., Ghosh S., Barkema H.W., Kaplan G.G. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012, 142:46-54.e42.
5. Cani P.D., Bibiloni R., Knauf C., Waget A., Neyrinck A.M., Delzenne N.M., Burcelin R. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet induced obesity and diabetes in mice. Diabetes 2008, 57:1470-1481.
6. de La Serre C.B., Ellis C.L., Lee J., Hartman A.L., Rutledge J.C., Raybould H.E. Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 299:G440-G448.
7. De Filippo C., Cavalieri D., Di Paola M., Ramazzotti M., Poullet J.B., Massart S., Collini S., Pieraccini G., Lionetti P. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:14691-14696.
8. Devkota S., Wang Y., Musch M.W., Leone V., Fehlner-Peach H., Nadimpalli A., Antonopoulos D.A., Jabri B., Chang E.B. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/-mice. Nature 2012, 487:104-108.
9. Chung W.K., Leibel R.L. Considerations regarding the genetics of obesity. Obesity 2008, 16:S33-S39.
10. Bax M., van Heemst J., Huizinga T.W.J., Toes R.E.M. Genetics of rheumatoid arthritis: what have we learned?. J. Immunogenet. 2011, 63:459-466.
11. Puiu M., Emandi A.C., Arghirescu S. Genetics and obesity, genetic disorders. Genetics and Obesity 2013, InTech. M. Puiu (Ed.).
12. Gathungu G.N., Cho J.H. The Genetics of Inflammatory Bowel Disease, Crohn's Disease and Ulcerative Colitis 2012, 3-16. Springer.
13. Bray G.A., Nielsen S.J., Popkin B.M. Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. Am. J. Clin. Nutr. 2004, 79:537-543.
14. Ferder L., Ferder M.D., Inserra F. The role of high-fructose corn syrup in metabolic syndrome and hypertension. Curr. Hypertens. Rep. 2010, 12:105-112.
15. Sekirov I., Russell S.L., Antunes L.C.M., Finlay B.B. Gut microbiota in health and disease. Physiol. Rev. 2010, 90:859-904.
16. Sartor R.B. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008, 134:577-594.
17. Savage D.C. Microbial ecology of the gastrointestinal tract. Annu. Rev. Microbiol. 1977, 31:107-133.
18. Crabbe P.A., Nash D.R., Bazin H., Eyssen H., Heremans J.F. Immunohistochemical observations on lymphoid tissues from conventional and germ-free mice. Lab. Invest. 1970, 22:448-457.
19. Turnbaugh P.J., Ridaura V.K., Faith J.J., Rey F.E., Knight R., Gordon J.I. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci. Transl. Med. 2009, 1:6ra14.
20. Reading N.C., Kasper D.L. The starting lineup: key microbial players in intestinal immunity and homeostasis. Front Microbiol. 2011, 2:148.
21. Wang Y., Devkota S., Musch M.W., Jabri B., Nagler C., Antonopoulos D.A., Chervonsky A., Chang E.B. Regional mucosa-associated microbiota determine physiological expression of TLR2 and TLR4 in murine colon. PLoS One 2010, 5:e13607.
22. Kleerebezem M., Vaughan E.E. Probiotic and gut lactobacilli and bifidobacteria: molecular approaches to study diversity and activity. Annu. Rev. Microbiol. 2009, 63:269-290.
23. Simopoulos A.P. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed. Pharmacother. 2002, 56:365-379.
24. Calder P.C. Polyunsaturated fatty acids and inflammatory processes: new twists in an old tale. Biochimie 2009, 91:791-795.
25. Calder P.C. Nutrition - links to the immune system. Encyclopedia of Lifestyle Medicine and Health 2012, 750-755. Sage, Los Angeles. J.M. Rippe (Ed.).
26. Leslie C.A., Gonnerman W.A., Ullman M.D., Hayes K.C., Franzblau C., Cathcart E.S. Dietary fish oil modulates macrophage fatty acids and decreases arthritis susceptibility in mice. J. Exp. Med. 1985, 162:1336-1349.
27. Ierna M., Kerr A., Scales H., Berge K., Griinari M. Supplementation of diet with krill oil protects against experimental rheumatoid arthritis. BMC Musculoskel. Dis. 2010, 11:136.
28. Scher J.U., Abramson S.B. The microbiome and rheumatoid arthritis. Nat. Rev. Rheumatol. 2011, 7:569-578.
29. Eerola E., Mottonen T., Hannonen P., Luukkainen R., Kantola I., Vuori K., Tuominen J., Toivanen P. Intestinal flora in early rheumatoid arthritis. Rheumatology 1994, 33:1030-1038.
30. Vaahtovuo J., Munukka E., Korkeamaki M., Luukkainen R., Toivanen P. Fecal microbiota in early rheumatoid arthritis. J. Rheumatol. 2008, 35:1500-1505.
31. Abdollahi-Roodsaz S., Joosten L.A.B., Koenders M.I., Devesa I., Roelofs M.F., Radstake T.R.D.J., Heuvelmans-Jacobs M., Akira S., Nicklin M.J.H., Ribeiro-Dias F., van den Berg W.B. Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. J. Clin. Invest. 2008, 118:205-216.
32. Wu H.-J., Wu E. The role of gut microbiota in immune homeostasis and autoimmunity. Gut. Microbe. 2012, 3:4-14.
33. Kozuch P.L., Hanauer S.B. General principles and pharmacology of biologics in inflammatory bowel disease. Gastroenterol. Clin. North Am. 2006, 35:757-773.
34. Lepage P., Seksik P., Sutren M., de la Cochetiere M.-F., Jian R., Marteau P., Dore J. Biodiversity of the mucosa associated microbiota is stable along the distal digestive tract in healthy individuals and patients with IBD. Inflamm. Bowel Dis. 2005, 11:473-480.
35. Ogura Y., Bonen D.K., Inohara N., Nicolae D.L., Chen F.F., Ramos R., Britton H., Moran T., Karaliuskas R., Duerr R.H. A frameshift mutation in NOD2 associated with susceptibility to crohn's disease. Nature 2001, 411:603-606.
36. Lesage S., Zouali H., Cezard J.-P., Colombel J.-F., Belaiche J., Almer S., Tysk C., O'Morain C., Gassull M., Binder V., Finkel Y., Modigliani R., Gower-Rousseau C., Macry J., Merlin F., Chamaillard M., Jannot A.-S., Thomas G., Hugot J.-P. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. J. Hum. Genet. 2002, 70:845-857.
37. Montgomery S.M., Ekbom A. Epidemiology of inflammatory bowel disease. Curr. Opin. Gastroenterol. 2002, 18:416-420.
38. Burkitt D.P. Related disease - related cause?. The Lancet 1969, 294:1229-1231.
39. Frank D.N., St. Amand A.L., Feldman R.A., Boedeker E.C., Harpaz N., Pace N.R. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:13780-13785.
40. Manichanh C., Borruel N., Casellas F., Guarner F. The gut microbiota in IBD. Nat. Rev. Gastroenterol. Hepatol. 2012, 9:599-608.
41. Shoelson S.E., Herrero L., Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 2007, 132:2169-2180.
42. Cani P.D., Amar J., Iglesias M.A., Poggi M., Knauf C., Bastelica D., Neyrinck A.M., Fava F., Tuohy K.M., Chabo C., Waget A., Delmee E., Cousin B., Sulpice T., Chamontin B., Ferrieres J., Tanti J.-F., Gibson G.R., Casteilla L., Delzenne N.M., Alessi M.C., Burcelin R. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007, 56:1761-1772.
43. Cani P., Neyrinck A., Fava F., Knauf C., Burcelin R., Tuohy K., Gibson G., Delzenne N. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 2007, 50:2374-2383.
44. Dixon J.B., Bhathal P.S., O'Brien P.E. Nonalcoholic fatty liver disease: predictors of nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in severely obese. Gastroenterology 2001, 121:91-100.
45. de Wit N.J.W., Afman L.A., Mensink M., Muller M. Phenotyping the effect of diet on non-alcoholic fatty liver disease. J. Hepatol. 2012, 57:1370-1373.
46. Collison K.S., Saleh S.M., Bakheet R.H., Al-Rabiah R.K., Inglis A.L., Makhoul N.J., Maqbool Z.M., Zaidi M.Z., Al-Johi M.A., Al-Mohanna F.A. Diabetes of the liver: the link between nonalcoholic fatty liver disease and HFCS-55. Obesity 2009, 17:2003-2013.
47. Gawrieh S., Marion M., Komorowski R., Wallace J., Charlton M., Kissebah A., Langefeld C., Olivier M. Genetic variation in the peroxisome proliferator activated receptor-gamma gene is associated with histologically advanced NAFLD. Dig. Dis. Sci. 2012, 57:952-957.
48. Charlton M., Krishnan A., Viker K., Sanderson S., Cazanave S., McConico A., Masuoko H., Gores G. Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am. J. Physiol. Gastrointest. Liver Physiol. 2011, 301:G825-G834.
49. Yang S.Q., Lin H.Z., Lane M.D., Clemens M., Diehl A.M. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:2557-2562.
50. Musso G., Gambino R., Cassader M. Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: mechanisms and implications for metabolic disorders. Curr. Opin. Lipidol. 2010, 21:76-83.
51. Rivera C.A., Adegboyega P., van Rooijen N., Tagalicud A., Allman M., Wallace M. Toll-like receptor-4 signaling and kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J. Hepatol. 2007, 47:571-579.
52. Tremaroli V., Backhed F. Functional interactions between the gut microbiota and host metabolism. Nature 2012, 489:242-249.
53. Davis B.K., Wen H., Ting J.P.Y. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu. Rev. Immunol. 2011, 29:707-735.
54. Henao-Mejia J., Elinav E., Jin C., Hao L., Mehal W.Z., Strowig T., Thaiss C.A., Kau A.L., Eisenbarth S.C., Jurczak M.J. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012, 179-185.
55. Henao-Mejia J., Elinav E., Jin C., Hao L., Mehal W.Z., Strowig T., Thaiss C.A., Kau A.L., Eisenbarth S.C., Jurczak M.J., Camporez J.-P., Shulman G.I., Gordon J.I., Hoffman H.M., Flavell R.A. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2011, 482:179-185.
56. Suganami T., Tanimoto-Koyama K., Nishida J., Itoh M., Yuan X., Mizuarai S., Kotani H., Yamaoka S., Miyake K., Aoe S., Kamei Y., Ogawa Y. Role of the toll-like receptor 4/NF-kB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler Thromb. Vasc. Biol. 2007, 27:84-91.
57. Milanski M., Degasperi G., Coope A., Morari J., Denis R., Cintra D.E., Tsukumo D.M.L., Anhe G., Amaral M.E., Takahashi H.K., Curi R., Oliveira H.C., Carvalheira J.B.C., Bordin S., Saad M.J., Velloso L.A. Saturated fatty acids produce an inflammatory response predominantly through the activation of TLR4 signaling in hypothalamus: implications for the pathogenesis of obesity. J. Neurosci. 2009, 29:359-370.
58. Caricilli A.M., Nascimento P.H., Pauli J.R., Tsukumo D.M.L., Velloso L.A., Carvalheira J.B., Saad M.J.A. Inhibition of toll-like receptor 2 expression improves insulin sensitivity and signaling in muscle and white adipose tissue of mice fed a high-fat diet. J. Endocrinol. 2008, 199:399-406.
59. Davis J.E., Gabler N.K., Walker-Daniels J., Spurlock M.E. Tlr-4 deficiency selectively protects against obesity induced by diets high in saturated fat. Obesity 2008, 16:1248-1255.
60. Vijay-Kumar M., Aitken J.D., Carvalho F.A., Cullender T.C., Mwangi S., Srinivasan S., Sitaraman S.V., Knight R., Ley R.E., Gewirtz A.T. Metabolic syndrome and altered gut microbiota in mice lacking toll-like receptor 5. Science 2010, 328:228-231.
61. Round J.L., Lee S.M., Li J., Tran G., Jabri B., Chatila T.A., Mazmanian S.K. The toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science 2011, 332:974-977.
62. Turnbaugh P.J., Ley R.E., Mahowald M.A., Magrini V., Mardis E.R., Gordon J.I. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006, 444:1027-1031.
63. Backhed F., Ding H., Wang T., Hooper L.V., Koh G.Y., Nagy A., Semenkovich C.F., Gordon J.I. The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:15718-15723.
64. Backhed F., Manchester J.K., Semenkovich C.F., Gordon J.I. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:979-984.
65. Upadhyay V., Poroyko V., Kim T.-j., Devkota S., Fu S., Liu D., Tumanov A.V., Koroleva E.P., Deng L., Nagler C., Chang E.B., Tang H., Fu Y.-X. Lymphotoxin regulates commensal responses to enable diet-induced obesity. Nat. Immunol. 2012, 13:947-953.
66. O'Flaherty S., Klaenhammer T.R. The role and potential of probiotic bacteria in the gut, and the communication between gut microflora and gut/host. Int. Dairy J. 2010, 20:262-268.
67. Ohland C.L., MacNaughton W.K. Probiotic bacteria and intestinal epithelial barrier function. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 298:G807-G819.
68. Pineda M.L., Thompson S.F., Summers K., de Leon F., Pope J., Reid G. A randomized, double-blinded, placebo-controlled pilot study of probiotics in active rheumatoid arthritis. Med. Sci. Monit. 2011, 17:CR347-CR354.
69. Claes I.J.J., De Keersmaecker S.C.J., Vanderleyden J., Lebeer S. Lessons from probiotic-host interaction studies in murine models of experimental colitis. Mol. Nutr. Food Res. 2011, 55:1441-1453.
70. Chang J.Y., Antonopoulos D.A., Kalra A., Tonelli A., Khalife W.T., Schmidt T.M., Young V.B. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J. Infect. Dis. 2008, 197:435-438.
71. Bakken J.S., Borody T., Brandt L.J., Brill J.V., Demarco D.C., Franzos M.A., Kelly C., Khoruts A., Louie T., Martinelli L.P., Moore T.A., Russell G., Surawicz C. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin. Gastroenterol. Hepatol. 2011, 9:1044-1049.
72. Eiseman B., Silen W., Bascom G.S., Kauvar A.J. Fecal enema as an adjunct in the treatment of Pseudomembranous enterocolitis. Surgery 1958, 44:854-859.
73. Petrof E.O., Gloor G.B., Vanner S.J., Weese S.J., Carter D., Daigneault M.C., Brown E.M., Schroeter K., Allen-Vercoe E. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut. Microbiome 2013, 1:1-12.
74. Gough E., Shaikh H., Manges A.R. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin. Infect. Dis. 2011, 53:994-1002.
75. Sartor R.B. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004, 126:1620-1633.
76. Hosseini E., Grootaert C., Verstraete W., Van de Wiele T. Propionate as a health-promoting microbial metabolite in the human gut. Nutr. Rev. 2011, 69:245-258.
77. Meijer K., de Vos P., Priebe M.G. Butyrate and other short-chain fatty acids as modulators of immunity: what relevance for health?. Curr. Opin. Clin. Nutr. Metab. Care 2010, 13:715-721.
78. May T., Mackie R.I., Fahey G.C., Cremin J.C., Garleb K.A. Effect of fiber source on short-chain fatty acid production and on the growth and toxin production by Clostridium difficile. Scand. J. Gastroenterol. 1994, 29:916-922.